17-Alpha-Hydroxyprogesterone Caproate for the Prevention of Preterm Birth in Women With Prior Preterm Birth and a Short Cervical Length

被引:1
|
作者
Berghella, Vincenzo [1 ]
Figueroa, Dana
Szychowski, Jeff M.
Owen, John
Hankins, Gary D. V.
Iams, Jay D.
Sheffield, Jeanne S.
Perez-Delboy, Annette
Wing, Deborah A.
Guzman, Edwin R.
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Obstet & Gynecol, Div Maternal Fetal Med, Philadelphia, PA 19107 USA
关键词
D O I
10.1097/OGX.0b013e3181f07822
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The primary risk factors for recurrent spontaneous preterm birth (SPTB) are a history of SPTB and a short cervical length (CL) found on second trimester transvaginal ultrasound (TVU). In women with prior SPTB or a short CL, the most frequently used interventions to prevent preterm birth (PTB) are cerclage and progesterone supplementation. It is unclear whether the effects of the progesterone agent 17-alpha-hydroxyprogesterone caproate (17P) are additive in women with both primary risk factors. It is also unclear whether 17P is beneficial for women with a prior SPTB and a short CL not undergoing TVU-indicated cerclage. The aim of this study was to evaluate the effect of 17P for the prevention of PTB in pregnant women with prior SPTB, and a short CL, with and without TVU-indicated cerclage. The study was a secondary analysis of a randomized controlled trial sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, evaluating cerclage for singleton women with prior SPTB (17-33 6/7 weeks), and CL < 25 mm between 16 and 22 6/7 weeks. The trial was conducted by 15 US clinical centers from 2003 through 2007. The women available for the final analysis were randomized to cerclage (n = 148) or no cerclage (n = 152). The primary study outcome was the effect of 17P on PTB < 35 weeks' gestation. The cerclage and no-cerclage groups were analyzed separately. The data showed that 17P had no effect on PTB < 35 weeks in women with or without cerclage (P = 0.64; P = 0.51, respectively). The use of 17P in the no-cerclage group significantly lowered the odds of PTB < 24 weeks (odds ratio [OR], 0.08; P = 0.0022) and perinatal death (OR, 0.14; P = 0.0029). These findings suggest that the use of 17P in women with prior SPTB who underwent TVU-indicated cerclage for short CL < 25 mm provides no additive benefit for prevention of PTB < 35 weeks. In women with these primary risk factors who did not receive cerclage, 17P was associated with reduced previable birth and perinatal mortality.
引用
收藏
页码:477 / 478
页数:2
相关论文
共 50 条
  • [41] Characteristics of women not receiving treatment with 17-alpha-hydroxyprogesterone-caproate for a history of spontaneous preterm birth
    Massa, Katherine
    Lawlor, Megan L.
    Boerrigter, Ashley
    Vricella, Laura K.
    Childress, Katherine S.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 222 (01) : S574 - S575
  • [42] Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth
    DeNoble, Anna E.
    Wynn, Clara E.
    Weaver, Kristin E.
    Wheeler, Sarahn M.
    Swamy, Geeta K.
    AMERICAN JOURNAL OF PERINATOLOGY, 2020, 37 (03) : 264 - 270
  • [43] Clinical Factors Associated with Use of 17-Hydroxyprogesterone Caproate for Prevention of Preterm Birth
    Yee, Lynn M.
    Liu, Lilly Y.
    Sakowicz, Allie
    Bolden, Janelle R.
    Miller, Emily S.
    REPRODUCTIVE SCIENCES, 2016, 23 : 106A - 107A
  • [44] Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17-hydroxyprogesterone caproate
    Combs, C. Andrew
    Garite, Thomas
    Maurel, Kimberly
    Das, Anita
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (01) : S205 - S205
  • [45] Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth
    Ning, Angela
    Vladutiu, Catherine J.
    Dotters-Katz, Sarah K.
    Goodnight, William H.
    Manuck, Tracy A.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 217 (03) : 371.e1 - 371.e7
  • [46] Racial and ethnic disparities in use of 17-hydroxyprogesterone caproate for prevention of preterm birth
    Yee, Lynn M.
    Liu, Lilly Y.
    Sakowicz, Allie
    Bolden, Janelle R.
    Miller, Emily S.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (01) : S12 - S13
  • [47] Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States
    Petrini, JR
    Callaghan, WM
    Klebanoff, M
    Green, NS
    Lackritz, EM
    Howse, JL
    Schwarz, RH
    Damus, K
    OBSTETRICS AND GYNECOLOGY, 2005, 105 (02): : 267 - 272
  • [48] Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth
    Caritis, Steve N.
    Venkataramanan, Raman
    Thom, Elizabeth
    Harper, Margaret
    Klebanoff, Mark A.
    Sorokin, Yoram
    Thorp, John M., Jr.
    Varner, Michael W.
    Wapner, Ronald J.
    Iams, Jay D.
    Carpenter, Marshall W.
    Grobman, William A.
    Mercer, Brian M.
    Sciscione, Anthony
    Rouse, Dwight J.
    Ramin, Susan
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2014, 210 (02) : 128.e1 - 128.e6
  • [49] A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth
    Nelson, David B.
    McIntire, Donald D.
    Leveno, Kenneth J.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 224 (02) : 175 - 186
  • [50] Effect of partial compliance on the prevention of recurrent preterm birth in women receiving weekly 17 alpha-hydroxyprogesterone caproate injections
    Haidar, Ziad A.
    Moussa, Hind N.
    Hosseini Nasab, Susan
    Sibai, Baha M.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2017, 30 (24): : 2926 - 2932